Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Aronora (Details)

v3.23.2
Royalty and Commercial Payment Purchase Agreements - Aronora (Details)
$ in Thousands
 1 Months Ended 6 Months Ended
Apr. 07, 2019
USD ($)
item
Sep. 30, 2019
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Agreements          
Payments of consideration under RPAs, AAAs and CPPAs     $ 14,650 $ 5,000  
Long-term royalty and commercial payment receivables     72,232   $ 63,683
Contingent consideration under RPAs, AAAs and CPPAs     1,000   75
Aronora | Royalty Purchase Agreement          
Agreements          
Number of drug candidates | item 5        
Non-royalties to be received (as a percent) 10.00%        
Future non-royalty payments to be received (as a percent) 5.00%        
Multiplier for cumulative amount of consideration paid | item 2        
Payments of consideration under RPAs, AAAs and CPPAs $ 6,000 $ 3,000      
Threshold amount of cumulative royalties on net sales per product 250,000        
Aggregate milestones payments per product 85,000        
Long-term royalty and commercial payment receivables 9,000        
Contingent consideration under RPAs, AAAs and CPPAs 3,000        
Amount of allowance for credit losses     $ 0   $ 0
Aronora | Royalty Purchase Agreement | SVB Loan          
Agreements          
Payments of consideration under RPAs, AAAs and CPPAs $ 3,000        
Aronora | Royalty Purchase Agreement | Bayer Products          
Agreements          
Number of drug candidates | item 3        
Number of drug candidates subject to exclusive license option | item 1        
Royalties entity has right to receive (as a percent) 100.00%        
Non-royalties to be received (as a percent) 10.00%        
Contingent future cash payment for each product $ 1,000        
Aronora | Royalty Purchase Agreement | Bayer Products | Maximum          
Agreements          
Potential future cash payments $ 3,000        
Aronora | Royalty Purchase Agreement | Non-Bayer Products          
Agreements          
Number of drug candidates | item 2        
Non-royalties to be received (as a percent) 10.00%